Navigation Links
Human Pheromone Sciences Announces Third Quarter Results
Date:11/13/2009

SAN JOSE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" or "the Company") today announced results for the three and nine month periods ended September 30, 2009. For the three months ending September 30, 2009, net revenues of $273,000 represented a 4% increase from the revenues of $262,000 in the prior year period, and resulted in net income of $10,000 ($0.00 per share) as compared with a net loss of $30,000 ($0.01 per share) for the same period of 2008. For the nine month period ending September 30, 2009, net revenues of $662,000 were 13% lower than the previous year's $764,000, resulting in a net loss of $255,000 ($0.06 per share) as compared with a net loss of $181,000 ($0.04 per share) in the first nine months of 2008.

According to a Company spokesperson, "the slight increase in revenues for the quarter is attributable to royalties generated under the expansion of our agreement with an additional U.S. subsidiary of the international chemical and consumer giant Schwarzkopf and Henkel (Dial Corporation). The launch of the Dial Body Wash Product containing our technology is very creative and exciting, and their website dedicated to these products, getmagnetic.com., is incredibly innovative, informative and entertaining. Somewhat offsetting these actual revenue increases, was a decrease in recognition of deferred revenue associated with the agreement entered into with Johnson & Johnson in 2006. The increased revenues from the higher margin royalty revenues contributed to net income of $10,000 in the current year third quarter as compared with a $30,000 loss in the same quarter lat year."

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction®, REALM®, innerREALM® and EROX® trademarks. These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the three and nine months ended September 30, 2009, as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                                 Tables follow



                           HUMAN PHEROMONE SCIENCES, INC.

                             Condensed Balance Sheets
                              (Dollars in thousands)



                                          September 30,          December 31,
                                               2009                  2008
                                               ----                  ----
                                           (Unaudited)             (Note 1)
    Assets

    Cash and cash equivalents           $       370            $        907
    Accounts receivable                         168                      52
    Inventories                                  45                      39
    Other current assets                         33                      58
    Property and equipment, net                   1                       2
                                                ---                     ---

    Total                               $       617            $      1,058
                                        ===========            ============

    Liabilities and shareholders' equity

    Accounts payable                    $        15            $         19
    Other current liabilities                   130                     131
    Deferred income - current                   220                     297
    Deferred income - non-current               188                     324
    Common stock                             21,075                  21,043
    Accumulated deficit                     (21,011)                (20,756)
                                            -------                 -------

    Total                               $       617            $      1,058
                                        ===========            ============

    Note 1 - Derived from audited financial statements



                               HUMAN PHEROMONE SCIENCES, INC.

                            Condensed Statements of Operations
                                       (Unaudited)
                       (Dollars in thousands, except per-share data)

                            Three months ended            Nine months ended
                               September 30,                 September 30,
                               ------------                  -------------
                          2009              2008          2009          2008
                          ----              ----          ----          ----

    Net revenue       $    273          $    262       $   662       $   764

    Cost of goods
     sold                   37                86           167           240
    Research and
     development            17                10            55            33
    Selling, general
     and
     administrative        209               203           696           696
                           ---               ---           ---           ---
    Income (loss)
     from operations        10               (37)         (256)         (205)

    Other income             -                 7             2            25


    Provision for
     income taxes            -                 -             1             1
                           ---               ---           ---           ---
    Net income
     (loss)           $     10          $    (30)      $  (255)      $  (181)
                      ========          ========       =======       =======

    Income (loss)
     per share -
       Basic:         $   0.00          $  (0.01)      $ (0.06)      $ (0.04)
                      ========          ========       =======       =======

       Fully
        diluted:      $   0.00          $  (0.01)      $ (0.06)      $ (0.04)
                      ========          ========       =======       =======


    Weighted average
     common shares
     outstanding-
       Basic:            4,152             4,152         4,152         4,152
                         =====             =====         =====         =====
       Fully
        diluted:         5,062             4,152         4,152         4,152
                         =====             =====         =====         =====

    Net loss per share is based on the weighted average number of common
    shares and common equivalents outstanding during each period.  Certain
    common stock equivalents are excluded when their effect would be
    anti-dilutive.

SOURCE Human Pheromone Sciences, Inc.


'/>"/>
SOURCE Human Pheromone Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Physicians for Human Rights Offers Training in Crime Scene Documentation
2. NIAID announces new human immunology research awards to help fight emerging infectious diseases
3. Not What the Doctor Ordered: Rapid Environmental Change Threatens the Foundations of Human Health
4. Precuneus region of human and monkey brain is divided into 4 distinct regions
5. NovaBays Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
6. Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award
7. MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative
8. Lockheed Martin Expands Health IT Business with $170 Million in New Health & Human Services Contract Awards
9. Babies Spot Human Speech at 5 Months
10. Scientists Discover Gene Key to Human Speech
11. Athens Consulting Volunteers Time To Habitat For Humanity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... 12, 2016 , ... Homeowners now have a next generation ... America’s leading brand of building products, has improved upon its industry-best array of ... version of the ColorView® Exterior Style and Color Selector. Created expressly for the ...
(Date:2/12/2016)... ... ... Healthcare careers in the medical laboratory, nursing, and in the imaging field ... staffing leader Aureus Medical Group during the month of January. Aureus Medical specializes in ... and in travel and direct hire opportunities in other allied health fields. , The ...
(Date:2/12/2016)... ... February 12, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... what he says are the real facts surrounding all those Bible stories. For generations ... Sunday school teachers, and Yisrayl says there is more to these than just mere ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Kalifornien, 12. Februar 2016  Sequent Medical, Inc. ... von Patienten für eine Studie zur Sicherheit und ... speziell für die Behandlung von rupturierten intrakraniellen Aneurysmen ... Leiter der Neuroradiologie an der Universitätsklinik Bicètre in ... der CLARYS-Studie hat den ersten Patienten aufgenommen. ...
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology: